Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous esketamine for severe psychotic depression
RBR-4n5f5jbPhase 3Recruiting
- Sponsor
- Universidade Federal da Bahia
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esketamine in major depressive disorder (2 arms), sponsored by Universidade Federal da Bahia. Started Apr 2023; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder
Beyond the preview
Go deeper on RBR-4n5f5jb.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4n5f5jb.